February 12, 2018 / 1:07 PM / 8 months ago

BRIEF-Pfizer says U.S., EU And Japan Health Authorities Accept Lorlatinib For Review

Feb 12 (Reuters) - Pfizer Inc:

* U.S., EU AND JAPAN HEALTH AUTHORITIES ACCEPT REGULATORY SUBMISSIONS FOR REVIEW OF PFIZER’S THIRD-GENERATION ALK INHIBITOR LORLATINIB

* PFIZER INC - U.S. NEW DRUG APPLICATION FOR LORLATINIB GRANTED FDA PRIORITY REVIEW Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below